These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10385510)

  • 21. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 23. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
    Donayre CE; Ouriel K; Rhee RY; Shortell CK
    J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin-directed inhibitors: pharmacology and clinical use.
    White CM
    Am Heart J; 2005 Jan; 149(1 Suppl):S54-60. PubMed ID: 15644794
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
    Berry CN; Girardot C; Lecoffre C; Lunven C
    Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The paradox of heparin-induced thrombocytopenia: the initial management.
    Taylor LM; Smith KM
    Orthopedics; 2005 Jun; 28(6):559-62. PubMed ID: 16138467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.
    Hayes JM; Jeske W; Callas D; Iqbal O; Fareed J
    Thromb Res; 1996 Apr; 82(2):187-91. PubMed ID: 9163072
    [No Abstract]   [Full Text] [Related]  

  • 28. Thrombin inhibitor design.
    Sanderson PE; Naylor-Olsen AM
    Curr Med Chem; 1998 Aug; 5(4):289-304. PubMed ID: 9668196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.
    Krupinski K; Basic-Micic M; Lindhoff E; Breddin HK
    Blut; 1990 Nov; 61(5):289-94. PubMed ID: 2176900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model.
    Zokai K; Piazolo L; Harenberg J
    Semin Thromb Hemost; 2001 Oct; 27(5):531-6. PubMed ID: 11668424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin.
    Wallén NH; Ladjevardi M; Albert J; Bröijersén A
    Thromb Res; 1997 Jul; 87(1):151-7. PubMed ID: 9253810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.
    Callas DD; Fareed J
    Thromb Res; 1996 Sep; 83(6):463-8. PubMed ID: 8885140
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
    Harenberg J; Zokai K; Piazolo L; Fenyvesi T; Jörg I
    Semin Thromb Hemost; 2002 Aug; 28(4):379-82. PubMed ID: 12244485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
    Maddineni J; Jeske WP; Baltasar F; Cornelli U; Manoni M; Hoppensteadt DA; Fareed J
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):311-7. PubMed ID: 16959684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
    Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
    Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of action and pharmacology of unfractionated heparin.
    Hirsh J; Anand SS; Halperin JL; Fuster V
    Arterioscler Thromb Vasc Biol; 2001 Jul; 21(7):1094-6. PubMed ID: 11451734
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibition of thrombin generation in recalcified plasma.
    Stief TW
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):751-60. PubMed ID: 17982316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
    Keularts IM; Béguin S; de Zwaan C; Hemker HC
    Thromb Haemost; 1998 Sep; 80(3):370-1. PubMed ID: 9759611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular approaches to antithrombotic therapy.
    Scharfstein J; Loscalzo J
    Hosp Pract (Off Ed); 1992 May; 27(5):77-86. PubMed ID: 1577892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of heparin and Bivalirudin on the kinetics of clot formation: Viscoelastic coagulation testing.
    Hasija S; Kapoor PM
    Ann Card Anaesth; 2017; 20(1):122. PubMed ID: 28074815
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.